Explore › Finding
Finding improvement
The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with no patient developing donor-specific antibody.
Effect size0/20 clinical acute rejections in first year
Follow-up1 year
ComparatorHistorical standard of care: calcineurin inhibitor-based regimen with maintenance steroids (used in >94% of transplant recipients)
Effect summaryimprovement; 0/20 clinical acute rejections in first year

Connected entities

Interventions
Alemtuzumab induction belatacept sirolimus
Conditions
kidney allograft rejection
Outcomes
Acute rejection of renal transplant

Source

PMC4642731
Renal Transplantation Using Belatacept Without Maintenance Steroids or Calcineurin Inhibitors
Read on PMC → · View in graph →